Database : MEDLINE
Search on : Peripheral and Nervous and System and Neoplasms [Words]
References found : 9342 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 935 go to page                         

  1 / 9342 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 28954297
[Au] Autor:Bandos H; Melnikow J; Rivera DR; Swain SM; Sturtz K; Fehrenbacher L; Wade JL; Brufsky AM; Julian TB; Margolese RG; McCarron EC; Ganz PA
[Ad] Address:NRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at
[Ti] Title:Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL). Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer. The AC→T group had a higher cumulative dose of T. PN was one of the symptoms assessed in a QOL substudy. Statistical methods included simple and mixed ordinal logistic regression and general linear models. All statistical tests were two-sided. Results: Of 1512 patients, 41.9% reported PN two years after treatment initiation. Treatment with AT and ACT was associated with less severe long-term PN compared with AC→T (odds ratio [OR] = 0.45, 95% confidence interval [CI] = 0.35 to 0.58; OR = 0.59, 95% CI = 0.46 to 0.75). Preexisting PN, older age, obesity, mastectomy, and greater number of positive nodes were also associated with higher risk of long-term PN. Patients who reported worse PN symptoms at 24 months had statistically significantly worse QOL (Ptrend < .001). Conclusions: The administration of docetaxel is associated with long-term PN. The lower rate of long-term PN in AT and ACT patients might be an important consideration in supporting choosing these therapies for individuals with preexisting neuropathic symptoms or other risk factors for neuropathy.
[Mh] MeSH terms primary: Antineoplastic Combined Chemotherapy Protocols/adverse effects
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Breast Neoplasms/drug therapy
Peripheral Nervous System Diseases/chemically induced
[Mh] MeSH terms secundary: Chemotherapy, Adjuvant
Cyclophosphamide/adverse effects
Doxorubicin/administration & dosage
Doxorubicin/adverse effects
Drug Administration Schedule
Female
Humans
Middle Aged
Quality of Life
Taxoids/administration & dosage
Taxoids/adverse effects
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Name of substance:0 (Taxoids); 15H5577CQD (docetaxel); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide)
[Em] Entry month:1710
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx162

  2 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28954296
[Au] Autor:Rivera DR; Ganz PA; Weyrich MS; Bandos H; Melnikow J
[Ad] Address:Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; Schools of Medicine and Public Health and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA; Center for Healthcare Policy and Research, University of California Davi
[Ti] Title:Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Breast cancer is the most common cancer among women worldwide, and survival rates are increasing. Chemotherapy-associated peripheral neuropathy (PN) is clinically important because of effects on quality of life (QOL) and potential effects on dose limitations. This adverse drug reaction is associated with certain classes of chemotherapy and commonly presents as peripheral sensory neuropathy whose natural course is largely unknown. The literature was reviewed to determine the frequency and characteristics of PN associated with adjuvant chemotherapy in early-stage breast cancer (ESBC) to explore the potential impact on long-term (one or more years after diagnosis) health outcomes and QOL. MEDLINE, PubMed, Embase, and the Cochrane Library were searched for relevant English-language randomized controlled trials, systematic reviews, meta-analyses, and case-control and cohort studies published between January 1990 and July 1996. Included studies were limited to current adjuvant regimens (eg, anthracyclines, taxanes, cyclophosphamide, platinum compounds). Two investigators independently reviewed abstracts, full-text articles, and extracted data from fair- and good-quality studies.Discrepancies in quality assessment and data extraction were resolved by consensus. We identified 364 articles; 60 were eligible for full-text review. Only five reports of four studies provided data beyond one year post-treatment initiation. Studies used different measures to assess PN. Neuropathic symptoms persisted in 11.0% to more than 80% of participants at one to three years following treatment. There is a paucity of data describing persistent PN in ESBC patients. Consistent use of validated measures and well-conducted randomized clinical trials or observational studies are needed to evaluate the incidence, persistence, and QOL associated with the long-term effects of PN.
[Mh] MeSH terms primary: Antineoplastic Agents/adverse effects
Breast Neoplasms/drug therapy
Breast Neoplasms/pathology
Peripheral Nervous System Diseases/chemically induced
[Mh] MeSH terms secundary: Antineoplastic Agents/therapeutic use
Female
Humans
Neoplasm Staging
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Antineoplastic Agents)
[Em] Entry month:1710
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx140

  3 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27775688
[Au] Autor:Nomura A; Majumder K; Giri B; Dauer P; Dudeja V; Roy S; Banerjee S; Saluja AK
[Ad] Address:Division of Surgical Oncology, Department of Surgery Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
[Ti] Title:Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer.
[So] Source:Lab Invest;96(12):1268-1278, 2016 12.
[Is] ISSN:1530-0307
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:NF-κB has an essential role in the initiation and progression of pancreatic cancer and specifically mediates the induction of epithelial-mesenchymal transition and invasiveness. In this study, we demonstrate the importance of activated NF-κB signaling in EMT induction, lymphovascular metastasis, and neural invasion. Modulation of NF-κB activity was accomplished through the specific NF-κB inhibitor (BAY 11-7085), triptolide, and Minnelide treatment, as well as overexpression of IKBα repressor and IKK activator plasmids. In the classical lymphovascular metastatic cascade, inhibition of NF-κB decreased the expression of several EMT transcription factors (SNAI1, SNAI2, and ZEB1) and mesenchymal markers (VIM and CDH2) and decreased in vitro invasion, which was rescued by IKK activation. This was further demonstrated in vivo via BAY 11-7085 treatment in a orthotopic model of pancreatic cancer. In vivo NF-κB inhibition decreased tumor volume; decreased tumor EMT gene expression, while restoring cell-cell junctions; and decreasing overall metastasis. Furthermore, we demonstrate the importance of active NF-κB signaling in neural invasion. Triptolide treatment inhibits Nerve Growth Factor (NGF) mediated, neural-tumor co-culture in vitro invasion, and dorsal root ganglia (DRG) neural outgrowth through a disruption in tumor-neural cross talk. In vivo, Minnelide treatment decreased neurotrophin expression, nerve density, and sciatic nerve invasion. Taken together, this study demonstrates the importance of NF-κB signaling in the progression of pancreatic cancer through the modulation of EMT induction, lymphovascular invasion, and neural invasion.
[Mh] MeSH terms primary: Epithelial-Mesenchymal Transition
NF-kappa B/metabolism
Pancreas/metabolism
Pancreatic Neoplasms/metabolism
Peripheral Nerves/metabolism
Peripheral Nervous System Neoplasms/secondary
Signal Transduction
[Mh] MeSH terms secundary: Animals
Antineoplastic Agents/pharmacology
Antineoplastic Agents/therapeutic use
Cell Line
Cell Line, Tumor
Coculture Techniques
Epithelial-Mesenchymal Transition/drug effects
Ganglia, Spinal/cytology
Ganglia, Spinal/drug effects
Ganglia, Spinal/metabolism
Ganglia, Spinal/pathology
Humans
Lymphatic Metastasis/pathology
Lymphatic Metastasis/prevention & control
Mice
Mice, Nude
NF-KappaB Inhibitor alpha/genetics
NF-KappaB Inhibitor alpha/metabolism
NF-kappa B/antagonists & inhibitors
Neoplasm Invasiveness/pathology
Neoplasm Transplantation
Pancreas/drug effects
Pancreas/pathology
Pancreatic Neoplasms/drug therapy
Pancreatic Neoplasms/pathology
Peripheral Nerves/cytology
Peripheral Nerves/drug effects
Peripheral Nerves/pathology
Peripheral Nervous System Neoplasms/metabolism
Peripheral Nervous System Neoplasms/pathology
Peripheral Nervous System Neoplasms/prevention & control
Recombinant Proteins/metabolism
Sciatic Nerve/cytology
Sciatic Nerve/drug effects
Sciatic Nerve/metabolism
Sciatic Nerve/pathology
Signal Transduction/drug effects
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (NF-kappa B); 0 (Recombinant Proteins); 139874-52-5 (NF-KappaB Inhibitor alpha)
[Em] Entry month:1706
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE
[do] DOI:10.1038/labinvest.2016.109

  4 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29427149
[Au] Autor:Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G
[Ad] Address:Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, 4650 Sunset Boulevard, MS #54, Los Angeles, CA, 90027, USA. nrobison@chla.usc.edu.
[Ti] Title:Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.
[So] Source:J Neurooncol;, 2018 Feb 09.
[Is] ISSN:1573-7373
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Single agent studies targeting the tumor microenvironment in central nervous system (CNS) tumors have largely been disappointing. Combination therapies targeting various pathways and cell types may be a more effective strategy. In this phase I study, we evaluated the combination of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory primary CNS tumors. Patients 1-21years old with relapsed or refractory CNS tumors were eligible. Starting doses of dasatinib and lenalidomide were 65mg/m /dose twice daily and 55mg/m once daily, respectively, while temozolomide was constant at 75mg/m daily. The study followed a 3 + 3 phase I design, with a 4-week dose-limiting toxicity (DLT) evaluation period. Serial peripheral blood lymphocyte subsets were evaluated in consenting patients. Fifteen patients were enrolled and thirteen were DLT-evaluable. DLTs occurred in 5 patients, including somnolence and confusion (1 patient), hypokalemia (1 patient) and thrombocytopenia (3 patients). The maximum tolerated dose for the combination was dasatinib 65mg/m twice daily, lenalidomide 40mg/m daily, and temozolomide 75mg/m daily, for 21days followed by 7days rest in repeating 28-day cycles. Transient increases in natural killer effector cells and cytotoxic T-cells were seen after 1week of treatment. One out of six response-evaluable patients showed a partial response. The combination was feasible and relatively well tolerated in this heavily pre-treated population. The most common toxicities were hematologic. Preliminary evidence of clinical benefit was seen.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180303
[Lr] Last revision date:180303
[St] Status:Publisher
[do] DOI:10.1007/s11060-018-2791-y

  5 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29390506
[Au] Autor:Anzai M; Morikawa M; Okuno T; Umeda Y; Demura Y; Sonoda T; Yamaguchi M; Kanno K; Shiozaki K; Ameshima S; Akai M; Ishizuka T
[Ad] Address:Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui.
[Ti] Title:Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.
[So] Source:Medicine (Baltimore);96(51):e9320, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC). METHODS: A phase II study was performed to assess the safety and efficacy of nab-PTX monotherapy as second-line chemotherapy after cytotoxic anticancer drugs for previously treated advanced NSCLC. Thirty-two patients with advanced NSCLC who had previously undergone 1 regimen of cytotoxic anticancer drugs were enrolled. Nab-PTX was administered intravenously at a dose of 100 mg/m on days 1, 8, and 15 of a 28-day cycle. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and toxicity profile were evaluated. RESULTS: The ORR was 28.1%, the DCR was 71.9%, median PFS was 3.9 months (95% confidence interval [CI] 2.7-5.1 months), and median OS was 10.9 months (95% CI 9.5-12.3 months). The mean relative dose intensity of nab-PTX was 77%. Grade 3 or 4 neutropenia, and grade 3 febrile neutropenia were observed in 11 and 1 of 32 patients, respectively. As nonhematologic toxicities, grade 3 peripheral sensory neuropathy and pneumonitis were each observed in 2 of 32 patients. CONCLUSION: Nab-PTX is an active and well-tolerated regimen in patients with previously treated NSCLC.
[Mh] MeSH terms primary: Albumin-Bound Paclitaxel/therapeutic use
Antineoplastic Agents/therapeutic use
Carcinoma, Non-Small-Cell Lung/drug therapy
Lung Neoplasms/drug therapy
[Mh] MeSH terms secundary: Aged
Anemia/chemically induced
Carcinoma, Non-Small-Cell Lung/mortality
Female
Humans
Japan/epidemiology
Lung Neoplasms/mortality
Male
Middle Aged
Neutropenia/chemically induced
Peripheral Nervous System Diseases/chemically induced
Pneumonia/chemically induced
Salvage Therapy
[Pt] Publication type:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Name of substance:0 (Albumin-Bound Paclitaxel); 0 (Antineoplastic Agents)
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009320

  6 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29461633
[Au] Autor:Baima JA; Silver JK; Most M
[Ad] Address:Department of Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School.
[Ti] Title:Neuromuscular dysfunction in the cancer patient: Evaluation and treatment.
[So] Source:Muscle Nerve;, 2018 Feb 20.
[Is] ISSN:1097-4598
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Cancer is a common diagnosis. In conjunction with various anti-neoplastic therapies delivered sequentially or concurrently, it makes oncology patients among the most complex to treat. This review uses a series of case studies to discuss the diagnosis and treatment of cancer-related nerve and muscle disorders. Oncologic treatment interventions such as surgery, chemotherapy, radiation therapy, and hormonal therapy, often have predictable side-effects, and sometimes their associated disability can be mitigated, especially if recognized early. Disease progression can mimic other diagnoses. The case studies provide a lens through which to study the presenting symptoms, differential diagnoses, diagnostic evaluation, and treatment interventions. These are all considered within the context of the patient's prognosis and health-related quality of life. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[St] Status:Publisher
[do] DOI:10.1002/mus.26103

  7 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29247745
[Au] Autor:Jiang ZF; Wang M; Xu JL
[Ad] Address:Department of Respiratory Medicine, National Key Clinical Specialist Construction Programs of China, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei 230022, Anhui, PR China. Electronic address: 1611601838@qq.com.
[Ti] Title:Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
[So] Source:Life Sci;194:1-6, 2018 Feb 01.
[Is] ISSN:1879-0631
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:AIMS: Thymidine kinase 1 (TK1) is a tumor biomarker in human malignancies. The purpose of this study was to evaluate the diagnostic efficiency of this marker for lung cancer using the combined analysis of carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), neuron specific enolase (NSE) and TK1. MAIN METHODS: From 2013 to 2014, 147 patients with lung cancer and 228 patients with lung benign diseases who were admitted to our hospital were reviewed. Peripheral blood samples were collected for the detection of TK1, CEA, CYFRA21-1 and NSE. The diagnostic value of each marker was analyzed using receiver operating characteristic (ROC) curves and logistic regression equations. KEY FINDINGS: The serum levels of TK1, CEA, CYFRA21-1 and NSE were significantly higher than those in patients with lung benign diseases (all P<0.05). The TK1 concentration was dependent on TNM stage (P=0.005). The ROC curve analyses showed that the diagnostic value of TK1 combined with CEA, CYFRA21-1 and NSE in lung cancer was significantly higher than that of each biomarker alone (all P<0.0001). In addition, TK1 combined with CEA, CYFRA21-1, or NSE could also improve the diagnosis of the squamous cell carcinoma, adenocarcinoma and small cell lung cancer subtypes, respectively. SIGNIFICANCE: The combined detection of TK1 and the other three markers significantly improved the diagnosis of lung cancer. Furthermore, the detection of TK1 combined with that of CYFRA21-1, CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and SCLC, respectively.
[Mh] MeSH terms primary: Antigens, Neoplasm/blood
Carcinoembryonic Antigen/blood
Keratin-19/blood
Lung Neoplasms/blood
Lung Neoplasms/diagnosis
Phosphopyruvate Hydratase/blood
Thymidine Kinase/blood
[Mh] MeSH terms secundary: Adenocarcinoma/blood
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor/blood
Carcinoma, Non-Small-Cell Lung/blood
Carcinoma, Squamous Cell/blood
Female
Humans
Male
Middle Aged
ROC Curve
Retrospective Studies
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (Carcinoembryonic Antigen); 0 (Keratin-19); 0 (antigen CYFRA21.1); EC 2.7.1.21 (Thymidine Kinase); EC 2.7.1.21 (thymidine kinase 1); EC 4.2.1.11 (Phosphopyruvate Hydratase)
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[Js] Journal subset:IM
[Da] Date of entry for processing:171217
[St] Status:MEDLINE

  8 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29175571
[Au] Autor:Plitt A; El Ahmadieh TY; Bindal S; Myers L; White J; Gluf W
[Ad] Address:Department of Neurological Surgery, University of Texas Southwestern, Dallas, Texas, USA.
[Ti] Title:Hypoglossal Schwannoma of Neck: Case Report and Review of Literature.
[So] Source:World Neurosurg;110:240-243, 2018 Feb.
[Is] ISSN:1878-8769
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Schwannomas are benign, slow-growing neoplasms of the myelin-producing Schwann cells of peripheral nervous system that most commonly affect sensory nerves. Hypoglossal schwannomas, tumors of purely motor nerves, comprise <5% of all head and neck schwannomas. Since the first description of a hypoglossal schwannoma in 1933, there have been few case reports of extracranial origins. The most common location of an extracranial hypoglossal schwannoma is in the parapharyngeal space and can mimic paragangliomas. We describe the case of a woman presenting with an enlarging neck mass originally thought to be a paraganglioma but ultimately discovered to be a hypoglossal schwannoma at surgery. CASE DESCRIPTION: A 63-year-old woman had a well-circumscribed, mobile, nontender, 3-cm firm mass at the mandibular angle. On computed tomography, the mass was at the level of the carotid bifurcation, splaying the branching vessels. It was further evaluated with magnetic resonance imaging, which revealed a homogeneous, T2-hyperintense, T1-isointense mass with homogeneous contrast enhancement and scant flow voids. Biopsy revealed a spindle cell mass with positive S-100 staining. She underwent resection with the mass originating from the hypoglossal nerve. CONCLUSIONS: Hypoglossal schwannomas are rare lesions with a variable location along the course of the nerve. An extracranial lesion was described here, which was initially mistaken for a paraganglioma. Surgical resection is the consensus recommendation and is often well tolerated with low risk of long-term recurrence.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[St] Status:In-Data-Review

  9 / 9342 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29245123
[Au] Autor:Fielder GC; Yang TW; Razdan M; Li Y; Lu J; Perry JK; Lobie PE; Liu DX
[Ad] Address:University of Auckland, Auckland, New Zealand.
[Ti] Title:The GDNF Family: A Role in Cancer?
[So] Source:Neoplasia;20(1):99-117, 2018 Jan.
[Is] ISSN:1476-5586
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The glial cell line-derived neurotrophic factor (GDNF) family of ligands (GFLs) comprising of GDNF, neurturin, artemin, and persephin plays an important role in the development and maintenance of the central and peripheral nervous system, renal morphogenesis, and spermatogenesis. Here we review our current understanding of GFL biology, and supported by recent progress in the area, we examine their emerging role in endocrine-related and other non-hormone-dependent solid neoplasms. The ability of GFLs to elicit actions that resemble those perturbed in an oncogenic phenotype, alongside mounting evidence of GFL involvement in tumor progression, presents novel opportunities for therapeutic intervention.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1712
[Cu] Class update date: 171226
[Lr] Last revision date:171226
[St] Status:In-Data-Review

  10 / 9342 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 29187478
[Au] Autor:Yamanouchi K; Kuba S; Sakimura C; Morita M; Kanetaka K; Kobayashi K; Takatsuki M; Hayashida N; Eguchi S
[Ad] Address:Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan ymanouch@gk9.so-net.ne.jp.
[Ti] Title:The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
[So] Source:Anticancer Res;37(12):6947-6951, 2017 12.
[Is] ISSN:1791-7530
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:BACKGROUND/AIM: Docetaxel often induces peripheral neuropathy (PN). The aim of this study was to elucidate the relationship between PN and systemic inflammation parameters, namely the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR). PATIENTS AND METHODS: We retrospectively evaluated 67 patients with breast cancer who were treated with docetaxel. Thirty patients (44.8%) had received previous chemotherapy including anthracycline. RESULTS: Overall, 51 patients (76.1%) experienced PN. All the parameters increased with the number of administered courses of docetaxel. In an analysis of patients without previous chemotherapy, those suffering from PN had a significantly higher NLR at the first and third cycles than those not suffering from PN (2.9 vs. 2.0, and 3.1 vs. 2.6, respectively, both p<0.05), and the MLR at the first cycle was also significantly higher in those with PN than in those without (0.18 vs. 0.15, p<0.05). CONCLUSION: Systemic inflammation appears to contribute to the occurrence of PN induced by docetaxel.
[Mh] MeSH terms primary: Breast Neoplasms/drug therapy
Inflammation/immunology
Peripheral Nervous System Diseases/immunology
Taxoids/adverse effects
[Mh] MeSH terms secundary: Adult
Aged
Antineoplastic Agents/adverse effects
Blood Platelets/immunology
Breast Neoplasms/immunology
Female
Humans
Leukocyte Count
Lymphocytes/immunology
Middle Aged
Monocytes/immunology
Neutrophils/immunology
Peripheral Nervous System Diseases/chemically induced
Platelet Count
Retrospective Studies
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (Taxoids); 15H5577CQD (docetaxel)
[Em] Entry month:1712
[Cu] Class update date: 171211
[Lr] Last revision date:171211
[Js] Journal subset:IM
[Da] Date of entry for processing:171201
[St] Status:MEDLINE


page 1 of 935 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information